ReviewCell cycle (Georgetown, Tex.)
SKP2 E3 ligase in urological malignancies: a critical regulator of the cell cycle and therapeutic target.
Review in Cell cycle (Georgetown, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating machine learning and structural analysis to decipher benzo[a]pyrene-induced bladder cancer networks.Discover oncology · 2026Article
- USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.Cell death & disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SKP2, an E3 ubiquitin ligase component of the SCF complex, plays a critical role in cell cycle regulation by targeting key inhibitors like p27, p21, and p57 for degradation, thereby promoting G1-S transition. Its overexpression is strongly associated with urological malignancies, including prostate, bladder, and kidney cancers, where it correlates with aggressive disease and poor prognosis. SKP2 drives tumor progression, via enhancing cancer cell proliferation, invasion, and metastasis. Targeting SKP2 through small molecule inhibitors or combination therapies holds promise for cancer treatment. However, challenges remain, including understanding its role in cancer stem cells, metastasis, and treatment resistance. Continued research is essential to harness SKP2's potential as a therapeutic target and biomarker for personalized medicine in urological cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.